Psyched: Biden’s Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Biden To Decide On Psychedelic Therapy Bill
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed
Clinical-stage psychedelics biotech Mind Medicine (MindMed) (NASDAQ: MNMD) has published new positive topline results from its Phase 2b study on a single dose of MM-120 (LSD tartrate,) with no additional therapeutic intervention, in Generalized Anxi
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy
Coca Leaf, Extract, Cocaine & Safe Supply: Grasping Potentials With Sector Incubator’s President Ronan Levy
Serious research is picking up on the potential mental health benefits of coca plant.
Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds
A COMPASS Pathways (NASDAQ: CMPS)-backed clinical trial assessing psilocybin-assisted psychotherapy for bipolar II disorder has provi
Psyched: Defense Dept.’s Ketamine Trial, Cybin’s Psilocybin, Metabolic Disorders, Reform Update And More
Defense Dept. Funds Ketamine Study For PTSD Treatment
Braxia Scientific’s Q2 2024: Cash Burn Over But Income Low, What’s Next For Psychedelics Company?
Ontario-based Canadian psychedelics company Braxia Scientific Corp. (OTC Pink: BRAXF) filed its interim financial statements and management discussion for the three and six months ended Sept. 30, 2023.
Numbers show:
Cybin’s Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What’s Next?
Next-generation psychedelics biotech Cybin Inc. (NYSE: CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing st
Red Light Holland, With $12M Cash Balance & Revenue Up 33%, Remains ‘Confident’ In Business Strategy
Canada-based all-mushroom producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements and management discussion and analysis for the three and six months ended Sept. 30, 2023.
Numbers show:
Seelos Therapeutics’ $5.55M Public Offering As Stock Drop 35%
Psychedelics biotech Seelos Therapeutics (NASDAQ: SEEL) announced the pricing of a new underwritten public offering for an estimated $5.5 million in gross proceeds. The offering is expected to close on or about Dec. 1, 2023.